Niki BioSolutions, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Niki BioSolutions merged with DiamiR Biosciences in an all-stock transaction closed July 20, 2026 (definitive agreement Oct 10, 2025; shareholder approval Jun 9, 2026). DiamiR comprises approximately 70% of the combined company; Aptorum approximately 30%. DiamiR brings a CLIA/CAP-licensed clinical lab in New Haven, CT, proprietary microRNA diagnostic technology for Alzheimer's disease and brain health, and a revenue-generating pharma-services platform (APOE genotyping generating revenue from Q3 2026).
Why this rating
Transformational for $18.7M-asset company. Merger adds revenue-generating diagnostics platform, licensed lab infrastructure, and significant IP portfolio. ~70/30 split materially dilutes Niki shareholders but introduces established revenue stream and clinical credibility in high-growth market.
Price action (we called it positive)
before filing · preread $5.84 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.